Revenue and profitability declined sharply year-over-year, but order intake increased and a SEK 12m rights issue strengthened liquidity. Strategic review with PharmaVentures and expanded marketing aim to drive future growth and maximize technology value.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.